Commerce Bank Sells 16,608 Shares of Kenvue Inc. (NYSE:KVUE)

Commerce Bank trimmed its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,023 shares of the company's stock after selling 16,608 shares during the period. Commerce Bank's holdings in Kenvue were worth $3,054,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in KVUE. Handelsbanken Fonder AB raised its position in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after purchasing an additional 21,222 shares in the last quarter. Alberta Investment Management Corp lifted its position in shares of Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after buying an additional 109,700 shares during the last quarter. Longbow Finance SA boosted its stake in Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after buying an additional 13,287 shares in the last quarter. Steward Partners Investment Advisory LLC grew its position in Kenvue by 143.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after acquiring an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. lifted its holdings in shares of Kenvue by 1.4% in the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after acquiring an additional 17,466 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 1.2 %

Kenvue stock traded up $0.28 during mid-day trading on Friday, reaching $23.03. The stock had a trading volume of 22,249,585 shares, compared to its average volume of 17,113,054. The firm has a market capitalization of $44.19 billion, a PE ratio of 43.45, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock's 50-day simple moving average is $23.03 and its 200-day simple moving average is $22.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio is currently 154.72%.

Analyst Ratings Changes

A number of brokerages have weighed in on KVUE. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Evercore ISI began coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Finally, Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.